Search

Your search keyword '"Poh, Mau Ern"' showing total 4 results
Start Over Author "Poh, Mau Ern" Topic adenocarcinoma
4 results on '"Poh, Mau Ern"'

1. Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers.

Author

Liam CK, Yew CY, Pang YK, Wong CK, Poh ME, Tan JL, Soo CI, Loh TC, Chin KK, Munusamy V, Liam YS, and Ibrahim NH

Subjects
Humans, Male, Female, B7-H1 Antigen genetics, B7-H1 Antigen metabolism, Smokers, Retrospective Studies, Anaplastic Lymphoma Kinase genetics, ErbB Receptors genetics, Mutation, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms pathology, Adenocarcinoma
Abstract

Background: In non-small cell lung cancer (NSCLC), there may be a relationship between programmed death-ligand 1 (PD-L1) expression, driver mutations and cigarette smoking., Methods: In this single-center retrospective study, the relationship between common driver mutations (EGFR mutation and ALK rearrangement) and PD-L1 expression in advanced NSCLC according to the patients' smoking history was examined. Light, moderate and heavy smokers had smoked < 20, 20-39, and ≥ 40 pack-years, respectively. The level of PD-L1 expression, assessed using Ventana SP263 monoclonal antibody assay, was defined by the tumor proportion score (TPS) as high expression (TPS ≥ 50%), low expression (TPS 1%-49%) and no expression (TPS < 1%)., Results: 101 (52.9%) of 191 advanced NSCLC patients were never smokers. EGFR mutations were more common in never smokers (64.4%) than in smokers (17.8%) with advanced NSCLC (P < 0.0001). A higher proportion of smokers (26.7%) had high PD-L1 expression compared to never smokers (13.9%) (P = 0.042). There was a trend for a higher proportion of male NSCLC patients [28 of 115 (24.3%)] than female patients [10 of 76 (13.2%)] to have high PD-L1 expression (P = 0.087]. High PD-L1 expression was seen in 32 of 110 (29.1%) patients with EGFR wild-type NSCLC but only in 6 of 81 (7.4%) patients with EGFR-mutant tumors (P < 0.0001). Among the 90 smokers with NSCLC, a higher proportion of heavy smokers (35.8%) than non-heavy smokers (13.5%) had high PD-L1 expression (P = 0.034). In patients with adenocarcinoma, high PD-L1 expression was seen in 25 of 77 (32.5%) patients with EGFR wild-type tumors but only in 4 of 70 (5.7%) patients with EGFR-mutant tumors (P < 0.0001). Among patients with adenocarcinoma, a significantly higher proportion of ever smokers (29.3%) than never smokers (13.5%) had high PD-L1 expression (P = 0.032). Among smokers with adenocarcinoma, a significantly higher proportion of heavy smokers (44.1%) than non-heavy smokers (8.3%) had high PD-L1 expression (P = 0.004). On multivariate analysis, after adjusting for gender and smoking status, heavy smoking and EGFR wild-type tumors remained significantly associated with high PD-L1 expression in NSCLCs and also in adenocarcinoma., Conclusions: Heavy smoking and EGFR wild-type tumors were significantly associated with high PD-L1 expression in NSCLCs and also in adenocarcinoma., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

3. Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients

Author

Liam Chong Kin, Tan Jiunn Liang, Chai Chee Shee, Pang Yong Kek, Poh Mau Ern, Kow Keng Siong, and Wong Chee Kuan

Subjects
Oncology, medicine.medical_specialty, Chemotherapy, Lung, Second line treatment, biology, business.industry, medicine.medical_treatment, Disease progression, Subgroup analysis, medicine.disease, Surgery, medicine.anatomical_structure, Internal medicine, medicine, biology.protein, Overall survival, Adenocarcinoma, Epidermal growth factor receptor, business
Abstract

Background Randomised control trials (RCTs) show good overall survival (OS) for advanced lung adenocarcinoma patients is much dependent on subsequent-line of treatment upon disease progression on first-line treatment. However, not many studies look into such outcome in real-world setting. Aims To determine the impact of second-line treatment on OS for advanced lung adenocarcinoma patients who failed first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) or chemotherapy in the real world-setting. Methods A retrospective analysis of advanced lung adenocarcinoma patients who developed disease progression on first-line EGFR-TKI or chemotherapy treatmentat the University of Malaya Medical Centre from 1 st August 2010 to 31 th July 2014. Results Of 78 patients with EGFR mutant tumours and failed first-line EGFR-TKI, 23 patients (29.5%) received second-line chemotherapy while remaining 56 patients (70.5%) had best supportive care (BSC). Subgroup analysis showed that patients who received second-line chemotherapy had numerically better median OS (12.60 months) than those received BSC (9.03 months) (HR, 0.53; 95% CI, 0.24-1.21; p=0.134). Of 79 patients with EGFR wild-type tumours and failed first-line chemotherapy, 36 patients (45.6%) received second-line chemotherapy and 43 patients (54.4%) had BSC - the median OS for the former was 11.50 months and the latter was 5.47 months (HR, 0.58; 95% CI, 0.34-0.98; p=0.043). Conclusions In the real-world setting, second-line active treatment significantly prolonged the OS. The OS in this study was shorter than that in RCTS due to presence of co-morbidities, poorer ECOG performance at diagnosis and lower rate of second-line treatment.

Published
2016

4. Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma

Author

Wong Chee Kuan, Pang Yong Kek, Tan Jiunn Liang, Chai Chee Shee, Liam Chong Kin, Poh Mau Ern, and Kow Keng Siong

Subjects
Oncology, medicine.medical_specialty, Chemotherapy, Lung, biology, business.industry, medicine.medical_treatment, Mutant, Retrospective cohort study, medicine.disease, respiratory tract diseases, Gefitinib, medicine.anatomical_structure, Internal medicine, medicine, biology.protein, Adenocarcinoma, heterocyclic compounds, Erlotinib, Epidermal growth factor receptor, business, neoplasms, medicine.drug
Abstract

Background Gefitinib and erlotinib are superior to chemotherapy in terms of progression-free-survival (PFS), objective response rate (ORR) and disease control rate (DCR)in patients with epidermal growth factor receptor (EGFR) mutant advanced lung adenocarcinoma. However, studies comparing the treatment efficacy of gefitinib versus erlotinib are lacking. Aims To compare the PFS, overall survival (OS), ORR and DCR of patients with EGFR mutant advanced lung adenocarcinoma receiving first-line gefitinib versus erlotinib in a real-world setting. Methods A retrospective study of patients with EGFR mutant advanced lung adenocarcinoma treated with first-line gefitinib 250 mg once daily versus erlotinib 150mg once dailyat the University of Malaya Medical Centre from 1st August 2010 to 31th July 2014. Results 80 patients (81.6%) received gefitinib and 18 patients (18.4%) received erlotinib as first-line treatment. There was no significant difference in terms of PFS [7.13 versus 6.03 months (HR, 0.73; 95% CI, 0.39 - 1.38; p=0.335)] or OS [10.97 versus 8.67 months (HR, 0.57; 95% CI, 0.27 – 1.22; p=0.148)] between the two treatment groups. Patients on first-line gefitinib had better ORR [45.0% versus 33.3% (OR, 1.94; 95% CI, 0.63 - 6.00; p=0.251)] but worse DCR [76.3% versus 94.4% (OR, 0.23; 95% CI, 0.03 - 1.93; p=0.175)] compared to patients on first-line erlotinib, but the differences were not statistically significant. Conclusions In a real-world setting, patients with EGFR mutant advanced lung adenocarcinoma treated with first-line gefitinib or erlotinib appeared to have similar PFS, OS, ORR and DCR. However, the apparent lack of differences could have been due to the small sample size.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results